Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040190 | 0.89 | PPARG (0.56) | RXFP1MEN1KMT2ANPC1LMNA | |
| Lithium Ion SCHEMBL7036038 | 0.83 | ALDH1A1 (0.53) | RXFP1MEN1KMT2ANPC1MAPT | |
| Lithium Ion SCHEMBL7037271 | 0.82 | PPARG (0.48) | RXFP1MEN1KMT2ANPC1LMNA | |
| Lithium Ion SCHEMBL7038144 | 0.78 | PPARG (0.61) | RXFP1MEN1KMT2ANPC1LMNA | |
| Lithium Ion SCHEMBL7035454 | 0.76 | RXFP1 (0.47) | RXFP1PPARGPTGS1PPARA | |
| SCHEMBL5944018 | 0.74 | PARP1 (0.67) | RXFP1MEN1KMT2ANPC1LMNA | |
| SCHEMBL7039689 | 0.72 | MAPT (0.55) | RXFP1MEN1KMT2ANPC1MAPT | |
| SCHEMBL5926550 | 0.71 | KIFC1 (0.58) | — | |
| SCHEMBL7038142 | 0.71 | IGF2BP2 (0.54) | KMT2ANPC1RAB9APPARGPPARD | |
| SCHEMBL7519747 | 0.71 | MAPT (0.82) | RXFP1MEN1KMT2ANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | RXFP1 258/4885MEN1 4333/4885KMT2A 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.